PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.36%
Revenue growth above 1.5x AVGO's 0.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
15.92%
Gross profit growth above 1.5x AVGO's 0.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
75.90%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
75.90%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
14.77%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
-15.38%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-16.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
50.74%
Share count expansion well above AVGO's 0.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
51.98%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-35.45%
Dividend reduction while AVGO stands at 0.14%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
109.22%
OCF growth above 1.5x AVGO's 7.23%. David Dodd would confirm a clear edge in underlying cash generation.
186.64%
FCF growth above 1.5x AVGO's 6.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-48.19%
Negative 10Y revenue/share CAGR while AVGO stands at 409.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
21.71%
5Y revenue/share CAGR under 50% of AVGO's 122.61%. Michael Burry would suspect a significant competitive gap or product weakness.
-38.73%
Negative 3Y CAGR while AVGO stands at 60.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
36.94%
10Y OCF/share CAGR under 50% of AVGO's 441.92%. Michael Burry would worry about a persistent underperformance in cash creation.
120.38%
5Y OCF/share CAGR above 1.5x AVGO's 73.80%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
8.97%
3Y OCF/share CAGR under 50% of AVGO's 34.25%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
71.28%
Below 50% of AVGO's 691.11%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
137.70%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-45.79%
Negative 3Y CAGR while AVGO is 66.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
127.57%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
59.18%
Below 50% of AVGO's 147.32%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-36.96%
Negative 3Y equity/share growth while AVGO is at 188.08%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-5.96%
Cut dividends over 10 years while AVGO stands at 1441.93%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-4.47%
Negative 5Y dividend/share CAGR while AVGO stands at 71.80%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-34.92%
Negative near-term dividend growth while AVGO invests at 38.29%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-4.66%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.11%
Inventory is declining while AVGO stands at 5.71%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.81%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-31.13%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.48%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-4.27%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.60%
We cut SG&A while AVGO invests at 14.12%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.